Easing Malaysia’s NCD economic burden: The case for generics and biosimilars

THE information in your report, "Healthcare crisis hitting all income groups" (Sept 8), is consistent with the feedback we receive first-hand from healthcare providers (HCPs), our own teams on the ground, and even friends during social occasions.

To me, the message is clear: Malaysia is facing a healthcare affordability crisis – and has been for some time. At the centre of this strain is the growing burden of non-communicable diseases (NCD) such as diabetes, heart disease and cancer. These conditions not only claim lives but also carry enormous financial cost for households, businesses and the nation’s economy.